Catalog No.
DHB90002
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG2-G4-kappa
Clonality
Monoclonal
Target
CPAMD4, C5, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, Complement C5
Concentration
3.38 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01031
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
5G1.1, h5G1.1HuG2/G4, CAS: 219685-50-4
Clone ID
Eculizumab
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use, PMID: 30402748
Eculizumab: A Review in Generalized Myasthenia Gravis, PMID: 29435915
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder, PMID: 32266705
Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics, PMID: 31703946
When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies, PMID: 30110670
Eculizumab in secondary atypical haemolytic uraemic syndrome, PMID: 28339660
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, PMID: 23738544
Eculizumab in pregnancy: a narrative overview, PMID: 30159857
Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial, PMID: 29685815
Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis, PMID: 27257797
[Eculizumab Treatment for Refractory Generalized Myasthenia Gravis], PMID: 31171753
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis, PMID: 30768680
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience, PMID: 32329881
Eculizumab for the treatment of myasthenia gravis, PMID: 32602752
Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature, PMID: 30598332
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study, PMID: 23623397
Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases, PMID: 30801549
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria, PMID: 16990386
Eculizumab is Efficacious But Often Not Accessible, PMID: 29746439
Eculizumab use in kidney transplantation, PMID: 26536427
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria, PMID: 31949012
Eculizumab, PMID: 18714106
Eculizumab, PMID: 19740388
High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine, PMID: 28704351
Eculizumab, PMID: 17715500
Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review, PMID: 30101319
Eculizumab for treatment of asthma, PMID: 22413827
Eculizumab as a treatment for atypical hemolytic syndrome secondary to carfilzomib, PMID: 29716757
Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria, PMID: 22085388
Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature, PMID: 31520126
Eculizumab in renal transplantation, PMID: 23747093
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria, PMID: 18055865
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis, PMID: 23512355
Eculizumab deposits in vessel walls in thrombotic microangiopathy, PMID: 31345584
Eculizumab: another breakthrough, PMID: 28232621
Eculizumab in Renal Transplantation: A 2017 Update, PMID: 28894081
Treating C3 glomerulopathy with eculizumab, PMID: 29329521
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome, PMID: 24249647
[C5: eculizumab], PMID: 25296873
[Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab], PMID: 30185704
Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence, PMID: 29288280
C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications, PMID: 30032749
Eculizumab in the treatment of membranoproliferative glomerulonephritis, PMID: 25402185
[Myasthenia gravis], PMID: 31538208
Eculizumab: A Complementary addition to existing long-term therapies for myasthenia gravis, PMID: 31074870
The use of eculizumab in renal transplantation, PMID: 23516966
Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases, PMID: 23486421
Atypical Hemolytic Uremic Syndrome, PMID: 29803280
Eculizumab in Acute Motor Axonal Neuropathy: An Ethical Application of an Off-Label Indication, PMID: 32833730
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria, PMID: 25356860
For research use only. Not for human or drug use.
